Skip to main content

Aroa Biosurgery Limited

Aroa's Symphony Shows 55% Wound Closure Rate in RCT vs 35%

Aroa's Symphony Shows 55% Wound Closure Rate in RCT vs 35%

Auckland – October 05, 2026 -- Aroa Biosurgery Limited (ASX: ARX) reported that its Symphony wound care product achieved a 55% complete closure rate for diabetic foot ulcers within 12 weeks, compared with 35% for standard of care alone, in a peer-reviewed randomized controlled trial published in the International Wound Journal.

Trial enrolled 143 patients across 10 U.S. sites to test Symphony against standard care

The prospective, multicenter RCT randomized patients with Wagner Grade 1 or 2 diabetic foot ulcers to receive either weekly Symphony plus standard of care or standard of care alone, for up to 12 weeks or until complete closure. Ulcers ranged from full-thickness skin wounds to deeper lesions extending into ligaments, tendons, joint capsules or deep fascia.

Aroa's Myriad Scaffold Shows 0.7% Deep Infection Rate in 411-Patient Study

Aroa's Myriad Scaffold Shows 0.7% Deep Infection Rate in 411-Patient Study

Auckland – September 09, 2026 -- Aroa Biosurgery Limited (ASX: ARX) reported that interim results from its MASTRR Registry found deep tissue infection in just 0.7% of patients treated with its Myriad Matrix and Myriad Morcells bioscaffolds, with no adverse events causally linked to the products.

Largest published prospective bioscaffold study covers 411 patients, 474 defects

The peer-reviewed analysis, published in Advances in Therapy, tracked 411 patients and 474 soft tissue defects across 10 US centers. Aroa says this represents, to its knowledge, the largest published prospective analysis of a bioscaffold in in-patient soft tissue reconstruction.